3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
4 citations
,
May 2011 in “Current Drug Discovery Technologies” A new liposomal system for applying dutasteride to the skin was developed, showing better skin absorption and stability, potentially improving treatment for hair loss.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
1 citations
,
October 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.
December 2024 in “Journal of Pharmaceutical Research International” The gel effectively delivers dutasteride for hair loss treatment and remains stable for 90 days.
12 citations
,
August 2019 in “Dermatitis” Dupilumab for skin problems might reactivate hair loss in some patients.
4 citations
,
January 2020 in “Journal of family medicine and primary care” Increasing Teneligliptin on his own caused a man's hair loss, which stopped when he ceased the medication.
May 2025 in “The Journal of Rheumatology” Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.
50 citations
,
December 2017 in “Nanoscale” Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
49 citations
,
December 2018 in “Journal of Investigational Allergology and Clinical Immunology” Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
3 citations
,
January 2018 in “Frontiers in bioscience” Daily subcutaneous testosterone effectively restores testosterone levels in men.
September 2024 in “Вопросы современной педиатрии” Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
80 citations
,
November 1975 in “Acta dermato-venereologica” Large doses of glucocorticoids are not suitable for general use in treating severe alopecia areata due to inconsistent results and risks.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
Dupilumab may worsen hair loss in patients with alopecia areata.
8 citations
,
October 2020 in “Pharmaceutics” Dutasteride-loaded nanoparticles coated with Lauric Acid-Chitosan show promise for treating hair loss due to their controlled release, low toxicity, and potential to stimulate hair growth.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
November 2021 in “International journal of life science and pharma research” The new gel for psoriasis is effective, stable, and easy to apply.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
13 citations
,
December 2020 in “BMJ Open Diabetes Research & Care” Changes in SHBG levels don't predict diabetes risk reduction.
44 citations
,
October 2016 in “Epilepsia” 2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.
21 citations
,
September 2019 in “International Journal of Nanomedicine” RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.